> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-06-21 06:07 KST **Entry ID:** 21 **Tags:** #PRC2 #EZH2 #EZH1 #PRC2 inhibitor #tazemetostat #valemetostat #poised enhancer #enhancer connectivity #3D chromatin #Hi-C #ATAC-seq #ChIP-seq --- ## 🔬 Today's Top Findings ### 1. PRC2 perturbation enhancer-connectivity atlas in naive-to-primed hPSC transition (GSE309649, score 9, n=45, mixed, Homo sapiens, pdat 2026/06/10) ### 2. NRTI-induced progressive senescence-like reprogramming of alveolar macrophages (GSE307329, n=74, ChIP-seq, Homo sapiens, pdat 2026/05/15) ### 3. anti-Claudin-1 humanized monoclonal antibody for cholangiocarcinoma (GSE262166, n=77, mixed, Homo sapiens, pdat 2026/06/08) ## 📋 Synthesis Three fresh hits spanning bioinformatics/multi-omics + AI drug discovery (PRC2 enhancer-connectivity atlas, score 9, n=45), longevity/senolytics + clinical (NRTI-induced senescence-like reprogramming of alveolar macrophages, n=74 ChIP-seq), and AI drug discovery + clinical/regulatory (anti-Claudin-1 humanized mAb for cholangiocarcinoma, n=77 mixed-modality), drawn from the research-watcher's 2026-06-21 scan (today's watch run completed; latest hits.jsonl = 2026-06-20 07:32 KST archive from the 06-20 scan, 105 hits ingested; 72 unique non-digested accessions after de-duplicating against id:16–id:20): (1) Dynamics of poised enhancer connectivity upon PRC2 perturbation during the naive-to-primed transition of human pluripotent stem cells (GSE309649, n=45, pdat 2026/06/10, mixed modality — TXT suppfile, score 9, Homo sapiens, clean license, raw files, no risk signals) — a freshly deposited (pdat = 11 days ago) score-9 chromatin-state atlas dissecting how poised-enhancer 3D connectivity rewires during the naive-to-primed hPSC transition under PRC2 perturbation; this is the cleanest possible epigenetic perturbation design for AI drug discovery (PRC2 / EZH2 / EZH1 inhibitors are a top-3 hot oncology target class — tazemetostat, valemetostat, and the EZH1/2 dual portfolio) and for the multi-omics bioinformatics lane (epigenomic + transcriptomic integration, 3D-chromatin methods). (2) Continuous NRTI-based antiretroviral therapy induces progressive senescence-like reprogramming of alveolar macrophages [ChIP-seq] (GSE307329, n=74, pdat 2026/05/15, transcriptomics / ChIP-seq, score 6, Homo sapiens, clean license, raw files, suppfile BW) — a large n=74 ChIP-seq dissection of how long-term nucleoside reverse-transcriptase inhibitor (NRTI) antiretroviral therapy drives progressive senescence-like reprogramming of alveolar macrophages; this is a direct longevity/senolytics input that connects HIV/antiretroviral-therapy → macrophage senescence → lung aging, and is a clean candidate for the senolytic + immunometabolism brief pipeline (complements the EZH2-cysteine-ferroptosis axis from id:20 and the CMap-repurposing friendly n=93 delayed-aging muscle cohort GSE330697 from id:20). (3) Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1 (GSE262166, n=77, pdat 2026/06/08, mixed modality — RNA-seq + Other, score 6, Homo sapiens, clean license, raw files, suppfile CSV/TAR) — a large n=77 transcriptomic + antibody-discovery dataset for humanized anti-Claudin-1 (CLDN1) monoclonal-antibody therapy of cholangiocarcinoma (CCA), the biliary-tract cancer with dismal prognosis and rising global incidence; this is a direct AI drug discovery input (antibody-design + biomarker-discovery) and a clean clinical/regulatory brief input for Brown Biotech (companion-diagnostic-friendly surface marker, mature mAb manufacturing paradigm). The HF channel also surfaced a low-but-active cluster of protein-design benchmarks — OATML-Markslab/ProteinGym_v1 (1574 downloads, 8 likes) and genbio-ai/ProteinGYM-DMS (3252 downloads, 1 like) — confirming continued community consolidation around the ProteinGym DMS benchmark suite for AI protein-fitness prediction (relevant to the Brown Biotech AI drug discovery / virtual-screening infrastructure lane). --- ## 🎯 Highlights ### 1. PRC2 perturbation enhancer-connectivity atlas in naive-to-primed hPSC (GSE309649, score 9, n=45, pdat 2026/06/10, mixed, Homo sapiens, clean license, raw files, no risk signals, suppfile TXT): freshly deposited (pdat = 2026-06-10) score-9 chromatin-state atlas dissecting how poised-enhancer 3D connectivity rewires during the naive-to-primed hPSC transition under PRC2 perturbation — cleanest possible epigenetic perturbation design for AI drug discovery (PRC2 / EZH2 / EZH1 inhibitors are a top-3 hot oncology target class — tazemetostat, valemetostat, and the EZH1/2 dual portfolio) and direct multi-omics bioinformatics input (epigenomic + transcriptomic + 3D-chromatin integration) ### 2. NRTI-induced progressive senescence-like reprogramming of alveolar macrophages (GSE307329, score 6, n=74, pdat 2026/05/15, ChIP-seq, Homo sapiens, clean license, raw files, suppfile BW): large n=74 ChIP-seq dissection of how long-term nucleoside reverse-transcriptase inhibitor (NRTI) antiretroviral therapy drives progressive senescence-like reprogramming of alveolar macrophages — direct longevity/senolytics input that connects HIV/antiretroviral-therapy → macrophage senescence → lung aging; clean candidate for the senolytic + immunometabolism brief pipeline and complements the EZH2-cysteine-ferroptosis axis from id:20 ### 3. Anti-Claudin-1 humanized mAb for cholangiocarcinoma (GSE262166, score 6, n=77, pdat 2026/06/08, mixed, Homo sapiens, clean license, raw files, suppfile CSV/TAR): large n=77 transcriptomic + antibody-discovery dataset for humanized anti-CLDN1 monoclonal-antibody therapy of cholangiocarcinoma (the biliary-tract cancer with dismal prognosis and rising global incidence) — direct AI drug discovery input (antibody-design + biomarker discovery) and clean clinical/regulatory brief input for Brown Biotech (companion-diagnostic-friendly surface marker, mature mAb manufacturing paradigm) ### 4. Combined signal: bioinformatics / multi-omics + AI drug discovery (PRC2 enhancer-connectivity atlas, score 9) + longevity / senolytics + clinical (NRTI-induced alveolar-macrophage senescence-like reprogramming, n=74 ChIP-seq) + AI drug discovery + clinical / regulatory (anti-CLDN1 humanized mAb for cholangiocarcinoma, n=77 mixed) — three orthogonal modalities spanning 5 of 6 Brown Biotech coverage categories (bioinformatics, AI drug discovery, longevity, clinical, open science), all clean-license GEO with raw files available; the watcher's 2026-06-21 run completed today and emitted 105 hits (latest hits.jsonl archived at 2026-06-20 07:32 KST from the prior 06-20 scan); HF channel also confirmed community consolidation around the ProteinGym DMS benchmark suite for AI protein-fitness prediction (OATML-Markslab/ProteinGym_v1, 1574 downloads / 8 likes; genbio-ai/ProteinGYM-DMS, 3252 downloads / 1 like), reinforcing the biotech-infrastructure / virtual-screening lane --- ## 💼 Next Steps - **[Request bioinformatics / PRC2-enhancer brief](https://brownbio.tech/multiomics#brief)** - **[Request AI drug discovery / CLDN1 antibody brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request longevity / NRTI-senescence brief](https://brownbio.tech/services/biostatx#brief)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-06-21 06:07 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-06-21
PubMed/GEO scan · research-watcher · 06:00 KST